Donaghue Foundation   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: West Hartford CT United States (1991)

Organization Overview

First Clinical Trial
2000
NCT00965562
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Donaghue Medical Research Foundation

Active Ingredients

Drugs in Phase 4 Trials (3)

calcium (2 trials)

orlistat (xenical) (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 3 Trials (2)

d-serine (2 trials)

multivitamins (1 trial)

Drugs in Phase 2 Trials (2)

mecamylamine (inversine) (1 trial)

varenicline (chantix) (1 trial)

Drugs in Other Trials (1)

fluoxetine (prozac) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Binge-Eating Disorder (Phase 4)

Bulimia (Phase 4)

Cognition Disorders (Phase 3)

Cognitive Dysfunction (Phase 3)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Frailty (Phase 4)

Obesity (Phase 4)

Osteoporosis (Phase 4)

Psychotic Disorders (Phase 3)

Schizophrenia (Phase 3)

Stomatitis (Phase 3)

Stomatitis, Aphthous (Phase 3)

Weight Loss (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 8